FIND-CKD study results for Ferinject (Vifor Pharma) for CKD+ Iron Deficiency

Results from the FIND-CKD study were presented at the American Society of Nephrology (ASN) Kidney Week in Atlanta, Georgia, USA. The FIND-CKD results demonstrate that Ferinject (ferric carboxymaltose) from Vifor Fresenius Renal Pharma, targeting a serum ferritin of 400-600 �g/L in patients with non-dialysis-dependent Chronic Kidney Disease (ND-CKD) and Iron Deficiency Anaemia significantly reduces or delays the need for alternative anaemia management (such as erythropoiesis-stimulating agents (ESAs) or blood transfusion).

Ferinject also results in a faster haemoglobin response with a greater proportion of patients achieving a Hb increase greater or equal to 1 g/dL. Furthermore, intravenous (i.v.) Ferinject was shown to be well-tolerated with fewer treatment-related adverse events and study discontinuations compared to oral iron.